Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea

This study provides mid-season estimates of the effectiveness of 2010/11 trivalent influenza vaccine and previous vaccination with monovalent influenza A(H1N1)2009 vaccine in preventing confirmed influenza A(H1N1)2009 infection in the United Kingdom in the 2010/11 season. The adjusted vaccine effectiveness was 34% (95% CI: -10 - 60%) if vaccinated only with monovalent vaccine in the 2009/10 season; 46% (95% CI: 7 - 69%) if vaccinated only with trivalent influenza vaccine in the 2010/11 season and 63% (95% CI: 37 - 78%) if vaccinated in both seasons.

Download Full-text

Faculty Opinions recommendation of Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718178091.793486987 ◽

2013 ◽

Author(s):

Graeme MacLaren

Keyword(s):

Acute Respiratory Distress Syndrome ◽

Cohort Study ◽

Extracorporeal Membrane Oxygenation ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Pandemic Influenza ◽

Influenza A ◽

Distress Syndrome ◽

Membrane Oxygenation ◽

Influenza A H1n1

Download Full-text

Faculty Opinions recommendation of Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7219957.7468055 ◽

2010 ◽

Author(s):

Simon Nadel ◽

Ajanta Kamal

Keyword(s):

Pandemic Influenza ◽

Influenza A ◽

Population Based ◽

H1n1 Infection ◽

Population Based Study ◽

Influenza A H1n1

Download Full-text

Expression of Surfactant protein D (SP-D) distinguishes severe pandemic influenza A(H1N1) from COVID-19

The Journal of Infectious Diseases ◽

10.1093/infdis/jiab113 ◽

2021 ◽

Author(s):

José Alberto Choreño-Parra ◽

Luis Armando Jiménez-Álvarez ◽

Gustavo Ramírez-Martínez ◽

Alfredo Cruz-Lagunas ◽

Mahima Thapa ◽

...

Keyword(s):

Pandemic Influenza ◽

Influenza A ◽

Alveolar Epithelium ◽

Surfactant Protein ◽

High Serum ◽

Surfactant Protein D ◽

Diagnostic Challenge ◽

Moderate Disease ◽

Influenza A H1n1 ◽

Novel Biomarkers

Abstract The differentiation of influenza and COVID-19 could constitute a diagnostic challenge during the ongoing winter due to their clinical similitude. Thus, novel biomarkers that enable distinguishing both diseases are required. Here, we evaluated whether the surfactant protein D (SP-D), a collectin produced at the alveolar epithelium with known immune properties, was useful to differentiate pandemic influenza A(H1N1) from COVID-19 in critically ill patients. Our results revealed high serum SP-D levels in severe pandemic influenza but not COVID-19 patients. This finding was validated in a separate cohort of mechanically ventilated COVID-19 patients who also showed low plasma SP-D levels. However, plasma SP-D levels did not distinguish seasonal influenza from COVID-19 in mild-to-moderate disease. Finally, we found that high serum SP-D levels were associated with mortality and renal failure among severe pandemic influenza cases. Thus, our studies have identified SP-D as a unique biomarker expressed during severe pandemic influenza but not COVID-19.

Download Full-text